Nalfon en es it fr

Nalfon Brand names, Nalfon Analogs

Nalfon Brand Names Mixture

  • No information avaliable

Nalfon Chemical_Formula


Nalfon RX_link

No information avaliable

Nalfon fda sheet

Nalfon FDA

Nalfon msds (material safety sheet)

Nalfon Synthesis Reference

No information avaliable

Nalfon Molecular Weight

427.537 g/mol

Nalfon Melting Point

No information avaliable

Nalfon H2O Solubility

Very slightly soluble

Nalfon State


Nalfon LogP


Nalfon Dosage Forms

Tablets (extended release - 500 mg)

Nalfon Indication

For the treatment of chronic angina. It should be used in combination with amlodipine, beta-blockers or nitrates.

Nalfon Pharmacology

Ranolazine has antianginal and anti-ischemic effects that do not depend upon reductions in heart rate or blood pressure. It is the first new anti-anginal developed in over 20 years.

Nalfon Absorption

Absorption is highly variable. After oral administration of ranolazine as a solution, 73% of the dose is systemically available as ranolazine or metabolites. The bioavailability of oral ranolazine relative to that from a solution is 76%.

Nalfon side effects and Toxicity

In the event of overdose, the expected symptoms would be dizziness, nausea/vomiting, diplopia, paresthesia, and confusion. Syncope with prolonged loss of consciousness may develop.

Nalfon Patient Information

AMITIZA™ may cause nausea. If this occurs, concomitant administration of food with AMITIZA™ may reduce symptoms of nausea. AMITIZA™ should not be administered to patients that have severe diarrhea. Patients should be aware of the possible occurrence of diarrhea during treatment. If the diarrhea becomes severe consult your physician.

Nalfon Organisms Affected

Humans and other mammals